S
ABBV icon

SignatureFD’s AbbVie ABBV Stock Holding History

SignatureFD’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12.3M Buy
56,557
+1,604
+3% +$356K 0.19% 46
2025
Q4 		$12.6M Buy
54,953
+838
+2% +$191K 0.19% 44
2025
Q3 		$12.5M Buy
54,115
+1,577
+3% +$321K 0.2% 45
2025
Q2 		$9.75M Buy
52,538
+251
+0.5% +$46.6K 0.17% 52
2025
Q1 		$11M Buy
52,287
+5,655
+12% +$1.1M 0.21% 49
2024
Q4 		$8.29M Sell
46,632
-62
-0.1% -$11.4K 0.16% 52
2024
Q3 		$9.22M Sell
46,694
-2,143
-4% -$400K 0.18% 48
2024
Q2 		$8.38M Buy
48,837
+628
+1% +$104K 0.17% 49
2024
Q1 		$8.78M Buy
48,209
+2,592
+6% +$447K 0.19% 47
2023
Q4 		$7.07M Sell
45,617
-1,365
-3% -$199K 0.16% 51
2023
Q3 		$7M Buy
46,982
+3,256
+7% +$478K 0.18% 45
2023
Q2 		$5.89M Sell
43,726
-3,638
-8% -$533K 0.15% 55
2023
Q1 		$7.55M Buy
47,364
+4,120
+10% +$630K 0.21% 42
2022
Q4 		$6.99M Buy
43,244
+1,408
+3% +$216K 0.2% 39
2022
Q3 		$5.62M Buy
41,836
+2,166
+5% +$311K 0.19% 37
2022
Q2 		$6.08M Sell
39,670
-346
-0.9% -$52.9K 0.21% 37
2022
Q1 		$6.49M Buy
40,016
+4,075
+11% +$592K 0.2% 40
2021
Q4 		$4.87M Buy
35,941
+4,193
+13% +$495K 0.15% 57
2021
Q3 		$3.42M Sell
31,748
-317
-1% -$36.2K 0.12% 63
2021
Q2 		$3.61M Buy
32,065
+2,549
+9% +$287K 0.14% 54
2021
Q1 		$3.19M Buy
29,516
+1,836
+7% +$196K 0.14% 55
2020
Q4 		$2.97M Buy
+27,680
New +$2.66M 0.14% 51
2020
Q3 		– Sell
-24,690
Closed -$2.42M – 2578
2020
Q2 		$2.42M Buy
24,690
+56
+0.2% +$4.93K 0.15% 49
2020
Q1 		$1.88M Sell
24,634
-6,325
-20% -$539K 0.16% 57
2019
Q4 		$2.74M Buy
30,959
+15,406
+99% +$1.28M 0.2% 41
2019
Q3 		$1.18M Sell
15,553
-1,080
-6% -$74K 0.1% 83
2019
Q2 		$1.21M Buy
16,633
+2,533
+18% +$199K 0.1% 75
2019
Q1 		$1.14M Sell
14,100
-953
-6% -$78K 0.1% 77
2018
Q4 		$1.39M Buy
15,053
+1,393
+10% +$123K 0.13% 66
2018
Q3 		$1.29M Sell
13,660
-6,341
-32% -$601K 0.13% 70
2018
Q2 		$1.85M Buy
20,001
+15
+0.1% +$1.47K 0.21% 52
2018
Q1 		$1.89M Buy
19,986
+8,882
+80% +$976K 0.22% 35
2017
Q4 		$1.07M Buy
11,104
+1,618
+17% +$152K 0.13% 66
2017
Q3 		$843K Buy
9,486
+30
+0.3% +$2.28K 0.11% 71
2017
Q2 		$686K Sell
9,456
-2,186
-19% -$147K 0.1% 77
2017
Q1 		$759K Buy
11,642
+2,914
+33% +$183K 0.11% 67
2016
Q4 		$547K Sell
8,728
-1,011
-10% -$61.7K 0.09% 88
2016
Q3 		$614K Buy
9,739
+4,250
+77% +$275K 0.09% 80
2016
Q2 		$340K Buy
5,489
+1,438
+35% +$87.6K 0.05% 122
2016
Q1 		$231K Buy
4,051
+1,142
+39% +$63.7K 0.04% 154
2015
Q4 		$172K Sell
2,909
-285
-9% -$16.4K 0.03% 161
2015
Q3 		$174K Buy
3,194
+161
+5% +$10.5K 0.04% 151
2015
Q2 		$204K Sell
3,033
-53
-2% -$3.46K 0.04% 142
2015
Q1 		$181K Buy
3,086
+473
+18% +$28.6K 0.04% 141
2014
Q4 		$171K Buy
2,613
+115
+5% +$7.25K 0.04% 146
2014
Q3 		$144K Sell
2,498
-159
-6% -$8.83K 0.05% 147
2014
Q2 		$150K Buy
2,657
+702
+36% +$36.8K 0.05% 145
2014
Q1 		$100K Sell
1,955
-3,704
-65% -$187K 0.04% 118
2013
Q4 		$299K Buy
5,659
+629
+13% +$30.9K 0.11% 60
2013
Q3 		$225K Buy
5,030
+32
+0.6% +$1.42K 0.1% 69
2013
Q2 		$207K Buy
+4,998
New +$219K 0.11% 75

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SignatureFD's ABBV Position: Q1 2026 in Review

SignatureFD increased its AbbVie (ABBV) stake by 2.9% in Q1 2026, buying an estimated $356K and bringing the position to 56,557 shares worth $12.3M. The position accounts for 0.19% of the portfolio, ranked #46.

SignatureFD first reported a position in ABBV in Q2 2013 and has held it in 51 quarters since. The position peaked at $12.6M in Q4 2025. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • SignatureFD held 56,557 shares of AbbVie worth $12.3M as of Q1 2026.
  • SignatureFD bought 1,604 AbbVie shares in Q1 2026, an estimated $356K.
  • AbbVie made up 0.19% of SignatureFD's portfolio in Q1 2026, its #46 holding.
  • SignatureFD first reported a position in AbbVie in Q2 2013 and has held it in 51 quarters since.
  • SignatureFD's AbbVie position peaked at $12.6M in Q4 2025.
  • 4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on SignatureFD's 13F filing for Q1 2026, filed 7 Apr 2026.